Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), UMRS_938, AP-HP Hôpital Saint-Antoine, F-75012, Paris, France.
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China.
Leukemia. 2020 May;34(5):1229-1240. doi: 10.1038/s41375-020-0804-2. Epub 2020 Apr 3.
Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (alloHCT) and is a major cause of morbidity and mortality. Systemic steroid therapy is the first-line treatment for aGVHD, although about half of patients will become refractory to treatment. As the number of patients undergoing alloHCT increases, developing safe and effective treatments for aGVHD will become increasingly important, especially for those whose disease becomes refractory to systemic steroid therapy. This paper reviews current treatment options for patients with steroid-refractory aGVHD and discusses data from recently published clinical studies to outline emerging therapeutic strategies.
急性移植物抗宿主病（aGVHD）是异基因造血干细胞移植（alloHCT）的常见并发症，也是发病率和死亡率的主要原因。全身类固醇治疗是 aGVHD 的一线治疗方法，尽管约有一半的患者会对治疗产生耐药性。随着接受 alloHCT 的患者数量增加，开发安全有效的 aGVHD 治疗方法将变得越来越重要，特别是对于那些疾病对全身类固醇治疗产生耐药性的患者。本文综述了目前治疗类固醇耐药性 aGVHD 的患者的治疗选择，并讨论了最近发表的临床研究数据，以概述新出现的治疗策略。
